Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice
Table 2
Treatment with surgical resection, radiotherapy, and chemotherapy by time period of glioblastoma diagnosis.
Treatment
Time period of diagnosis
P-value1
1995-2004
2005-2012
n = 163
n = 144
n (%)
n (%)
Surgical resection
100 (61.3)
80 (55.6)
0.30
Any radiotherapy
106 (65.0)
112 (77.8)
0.014
60 Gray of radiation
66 (40.5)
81 (56.3)
0.0058
Any chemotherapy
63 (38.7)
113 (78.5)
< 0.0001
Temozolomide chemotherapy
18 (11.0)
112 (77.8)
< 0.0001
Other (non-temozolomide) chemotherapy
45 (27.6)
1 (0.7)
< 0.0001
Concomitant and adjuvant temozolomide chemotherapy
2 (1.2)
60 (41.7)
< 0.0001
Standard treatment2
1 (0.6)
52 (36.1)
< 0.0001
Radiotherapy without chemotherapy
50 (30.7)
5 (3.5)
< 0.0001
No radiotherapy and no chemotherapy
50 (30.7)
26 (18.1)
0.011
Chi-squared test used to compare the percentage of patients between the two time periods. Standard treatment was maximal safe surgery, postoperative administration of 60 Gray of radiation, completion of concomitant temozolomide chemotherapy, and completion of at least one cycle of adjuvant temozolomide.
